Metmin (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the nasal mucosa, altering gene expression to suppress inflammatory mediators. This reduces swelling, mucus production and cellular infiltration, providing symptomatic relief in the nasal passages.

The prescribed dose of Metmin is determined by a qualified healthcare professional based on the patient’s condition, age and response. Typical regimens follow the product label, but exact dosing should always be confirmed by the prescriber.

Safety data for mometasone furoate in pregnancy and lactation are limited. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Metmin.

To order Metmin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metmin (mometasone furoate) is a high‑potency intranasal corticosteroid with a favorable safety profile when used at recommended doses. Compared with older agents such as beclomethasone, it offers greater anti‑inflammatory potency and once‑daily dosing convenience, while maintaining low systemic absorption.

Store Metmin at room temperature, away from direct sunlight and moisture. Keep the spray in its original packaging until use, and ensure the cap is tightly closed after each application to maintain product integrity.

Metmin is administered as a nasal spray. The patient should gently blow the nose, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious risks include nasal septal perforation, severe allergic reactions such as anaphylaxis, and adrenal suppression with prolonged high‑dose use. Patients should seek immediate medical attention if they experience unusual bleeding, persistent nose pain, or signs of systemic corticosteroid effects.

Metmin should be avoided in individuals with known hypersensitivity to mometasone furoate or any component of the formulation, and in patients with active untreated nasal infections. Caution is also advised for those with uncontrolled glaucoma, cataracts or severe systemic infections.